SOPHiA Genetics Combines In Vivo And In Vitro Cancer Analyses With Enhanced AI Platform
Clinical genomics company SOPHiA Genetics is integrating new radiomics capabilities to enhance its artificial intelligence (AI) platform SOPHiA, which is already used for analyses of oncology data from liquid biopsy tests. The news marks an increasing trend toward integrating in vivo and in vitro data onto a single diagnostic platform.
You may also be interested in...
Offering a challenging but blossoming free market model, strong academic institutions and an excellent track record in patents, the Swiss Biotech industry is one to watch.
In a move to accelerate adoption of its AI-driven genomics platform, SOPHiA Genetics has acquired Interactive Biosoftware, the French developer of Alamut, a clinical decision support software used in genomic data interpretation.
The goliaths of imaging and in vitro diagnostics have sealed a pact to codevelop a new data analytics platform for faster clinical decision-making, more accurate diagnosis and more personalized treatments.